Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityOther Accumulated ExpensesPayablesPrepaid AssetsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Other Accumulated Expenses (2016 - 2025)

Historic Other Accumulated Expenses for Marker Therapeutics (MRKR) over the last 11 years, with Q3 2025 value amounting to $328315.0.

  • Marker Therapeutics' Other Accumulated Expenses fell 6365.94% to $328315.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $328315.0, marking a year-over-year decrease of 6365.94%. This contributed to the annual value of $1.7 million for FY2024, which is 2860.9% up from last year.
  • Marker Therapeutics' Other Accumulated Expenses amounted to $328315.0 in Q3 2025, which was down 6365.94% from $656631.0 recorded in Q2 2025.
  • In the past 5 years, Marker Therapeutics' Other Accumulated Expenses registered a high of $1.7 million during Q4 2024, and its lowest value of $38000.0 during Q4 2022.
  • Over the past 5 years, Marker Therapeutics' median Other Accumulated Expenses value was $354000.0 (recorded in 2024), while the average stood at $484432.2.
  • In the last 5 years, Marker Therapeutics' Other Accumulated Expenses tumbled by 8480.0% in 2022 and then soared by 340000.0% in 2023.
  • Quarter analysis of 5 years shows Marker Therapeutics' Other Accumulated Expenses stood at $250000.0 in 2021, then plummeted by 84.8% to $38000.0 in 2022, then surged by 3400.0% to $1.3 million in 2023, then increased by 28.61% to $1.7 million in 2024, then plummeted by 80.81% to $328315.0 in 2025.
  • Its last three reported values are $328315.0 in Q3 2025, $656631.0 for Q2 2025, and $411327.0 during Q1 2025.